Thanks to those who replied. I have listened to the webcast, but feel that I probably need to listen again more than once, and then ask questions to grasp the significance of some of the points. It is somewhat concerning that 591 will be entering the market not just with Pluvicto established, but perhaps also with the therapy acquired in Eli Lilly's takeover, and how many others. Perhaps hard to make headway then .
Of course, the renal and brain diagnostics and perhaps also therapies make the current SP seem undervalued .
TLX Chart, page-1222
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.61 |
Change
0.150(0.91%) |
Mkt cap ! $5.549B | |||
| Open | High | Low | Value | Volume |
| $16.50 | $16.86 | $16.02 | $30.84M | 1.870M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3364 | $16.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.63 | 2703 | 2 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$16.64 |
Change
0.150 ( 0.47 %) |
||||
| Open | High | Low | Volume | ||
| $16.49 | $16.86 | $16.02 | 314899 | ||
| Last updated 15.59pm 14/06/2024 ? | |||||
| TLX (ASX) Chart |